Overall survival is doubled in patients with metastatic NSCLC treated with pembrolizumab in combination with chemotherapy compared to chemo alone, a phase 3 trial has confirmed. In findings released at the American Association for Cancer Research (AACR) annual meeting in Chicago, the KEYNOTE-189 study showed significant benefits for pembrolizumab combined with pemetrexed and a platinum-based drug ...
Phase 3 trials confirm benefits for immune therapies in NSCLC
By Michael Woodhead
18 Apr 2018